FDA Renews Psychopharmacologic Drugs Advisory Committee
Published Date: 5/29/2026
Notice
Summary
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for two more years, keeping it active until June 4, 2028. This committee helps make sure psychiatric drugs are safe and effective, affecting drug makers, doctors, and patients. No new costs or big changes, just a smooth continuation of expert advice to keep mental health treatments on track.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Clozapine REMS Participation Changed (2024)
The committee's 2024 recommendations informed the FDA's decision to no longer expect prescribers, pharmacies, and patients to participate in the Clozapine REMS program or to report absolute neutrophil count (ANC) blood test results before pharmacies dispense clozapine. That change reduced procedural obligations for prescribers, pharmacies, and patients related to clozapine access.
Psychiatric Advisory Panel Renewed
The FDA renewed the Psychopharmacologic Drugs Advisory Committee for an additional two years, with the new charter in effect until June 4, 2028. The committee will continue to provide expert advice aimed at ensuring psychiatric drugs are safe and effective, affecting drug makers, prescribers, and patients; the notice states there are no new costs or major changes with this renewal.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-10673, Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest
The U.S. International Trade Commission got a complaint from Caterpillar about some heavy machinery parts being imported and sold unfairly by Doosan Bobcat companies around the world. They want to stop these imports and sales while the case is reviewed, which could affect businesses and buyers soon. The public and other groups have a chance to share their thoughts before any decisions are made.
Next: 2026-10676, Caribou-Targhee National Forest; Wyoming; Amendment to the 1997 Land Management Plan for the Targhee National Forest
The Forest Service is updating the 1997 Targhee National Forest Plan to allow the Grand Targhee ski resort to expand by changing how 694 acres of forest land are used. This affects local outdoor lovers and businesses by turning some protected areas into special recreation zones. People have 60 days to raise any concerns before the changes get final approval.